Hyperthermia, cisplatin and radiation trimodality treatment: A promising cancer treatment? A review from preclinical studies to clinical application

References

• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–497
   PubMed Web of Science ®Google Scholar
• van der Zee J. Heating the patient: A promising approach?. Ann Oncol 2002; 13: 1173–1184
   PubMed Web of Science ®Google Scholar
• van der Zee J, Treurniet-Donker AD, The SK, Helle PA, Seldenrath JJ, Meerwaldt JH, Wijnmaalen AJ, van den Berg AP, van Rhoon GC, Broekmeyer-Reurink MP. Low dose reirradiation in combination with hyperthermia: A palliative treatment for patients with breast cancer recurring in previously irradiated areas. Int J Radiat Oncol Biol Phys 1988; 15: 1407–1413
   PubMed Web of Science ®Google Scholar
• Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 535–549
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gonzalez GD, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119–1125
   PubMed Web of Science ®Google Scholar
• Datta NR, Bose AK, Kapoor HK, Gupta S. Head and neck cancers: Results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia 1990; 6: 479–486
   PubMed Web of Science ®Google Scholar
• Overgaard J, Gonzalez GD, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345: 540–543
   PubMed Web of Science ®Google Scholar
• Perez CA, Pajak T, Emami B, Hornback NB, Tupchong L, Rubin P. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol 1991; 14: 133–141
   PubMed Web of Science ®Google Scholar
• Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1994; 28: 163–169
   PubMed Web of Science ®Google Scholar
• Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der ZJ, van Putten WL, van Rhoon GC, van Dijk JD, Gonzalez GD, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35: 731–744
   PubMed Web of Science ®Google Scholar
• Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 2001; 17: 97–105
   PubMed Web of Science ®Google Scholar
• Dahl O. Editorial: Clinical hyperthermia combined with radiation is safe. Int J Hyperthermia 2005; 21: 193–197
   PubMed Web of Science ®Google Scholar
• Alberts DS, Peng YM, Chen HS, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 1980; 65: 455–461
   PubMed Web of Science ®Google Scholar
• Haveman J, Bergs JW, Franken NA, van Bree C, Stalpers LJ. Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells. Oncol Rep 2005; 14: 561–567
   PubMed Web of Science ®Google Scholar
• Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 1980; 40: 1136–1139
   PubMed Web of Science ®Google Scholar
• Miyahara T, Ueda K, Akaboshi M, Shimada Y, Imamura M, Utsumi H. Hyperthermic enhancement of cytotoxicity and increased uptake of cis-diamminedichloroplatinum(II) in cultured human esophageal cancer cells. Jpn J Cancer Res 1993; 84: 336–340
   PubMedGoogle Scholar
• Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol 1994; 34: 302–306
   PubMed Web of Science ®Google Scholar
• Ohtsubo T, Saito H, Tanaka N, Noda I, Saito T, Kano E. Effect of heat-drug sequences on thermoenhancement and uptake of cis-DDP in human pharyngeal carcinoma. Anticancer Res 1996; 16: 297–300
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Yang DP. The evaluation of thermal cisplatin sensitization in normal and XP human cells using mild hyperthermia at 40 and 41°C. Anticancer Res 2005; 25: 2649–2653
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Li LF, Yang DP, LeBlanc JM. Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair. Oncol Rep 2005; 14: 281–285
   PubMedGoogle Scholar
• Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24: 1561–1567
   PubMed Web of Science ®Google Scholar
• Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003; 21: 799–806
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 686–691
   PubMed Web of Science ®Google Scholar
• Douwes F, Bogovic J, Douwes O, Migeod F, Grote C. Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer. Int J Clin Oncol 2004; 9: 85–91
   PubMedGoogle Scholar
• Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, III, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154–1161
   PubMed Web of Science ®Google Scholar
• Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137–1143
   PubMed Web of Science ®Google Scholar
• Peters WA, III, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W, Jr., Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–1613
   PubMed Web of Science ®Google Scholar
• Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Clarke-Pearson DL, Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339–1348
   PubMed Web of Science ®Google Scholar
• Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, Bruno S, Grossi F, Scolaro T, Ardizzoni A. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer 2001; 33: 27–39
   PubMedGoogle Scholar
• Begg AC, van der Kolk PJ, Dewit L, Bartelink H. Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1986; 50: 871–884
   PubMed Web of Science ®Google Scholar
• Huang H, Huang SY, Chen TT, Chen JC, Chiou CL, Huang TM. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells. J Cell Biochem 2004; 91: 756–765
   PubMed Web of Science ®Google Scholar
• Nakamoto S, Mitsuhashi N, Takahashi T, Sakurai H, Niibe H. An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Int J Radiat Biol 1996; 70: 747–753
   PubMed Web of Science ®Google Scholar
• Myint WK, Ng C, Raaphorst GP. Examining the non-homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol 2002; 78: 417–424
   PubMed Web of Science ®Google Scholar
• Dolling JA, Boreham DR, Brown DL, Raaphorst GP, Mitchel RE. Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res 1999; 433: 127–136
   PubMedGoogle Scholar
• Herman TS, Jochelson MS, Teicher BA, Scott PJ, Hansen J, Clark JR, Pfeffer MR, Gelwan LE, Molnar-Griffin BJ, Fraser SM. A phase I–II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies. Int J Radiat Oncol Biol Phys 1989; 17: 1273–1279
   PubMed Web of Science ®Google Scholar
• Bornstein BA, Zouranjian PS, Hansen JL, Fraser SM, Gelwan LA, Teicher BA, Svensson GK. Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 79–85
   PubMed Web of Science ®Google Scholar
• Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, Maluta S, Valdagni R. Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: A phase I–II study. Int J Radiat Oncol Biol Phys 1993; 26: 801–807
   PubMedGoogle Scholar
• Schreiber DP, Overett TK. Interstitial hyperthermia and iridium-192 treatment alone vs. interstitial iridium-192 treatment/hyperthermia and low dose cisplatinum infusion in the treatment of locally advanced head and neck malignancies. Int J Radiat Oncol Biol Phys 1995; 33: 429–436
   PubMedGoogle Scholar
• Feyerabend T, Steeves R, Wiedemann GJ, Weiss C, Wagner T, Richter E, Robins HI. Local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Oncology 1996; 53: 214–220
   PubMedGoogle Scholar
• Serin M, Erkal HS, Cakmak A. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with recurrent carcinomas of the head and neck with metastatic cervical lymph nodes. Int J Hyperthermia 1999; 15: 371–381
   PubMed Web of Science ®Google Scholar
• Serin M, Erkal HS, Cakmak A. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes. Radiother Oncol 1999; 50: 103–106
   PubMed Web of Science ®Google Scholar
• Saeki H, Kawaguchi H, Kitamura K, Ohno S, Sugimachi K. Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. J Surg Oncol 1998; 69: 224–229
   PubMed Web of Science ®Google Scholar
• Morita M, Kuwano H, Araki K, Egashira A, Kawaguchi H, Saeki H, Kitamura K, Ohno S, Sugimachi K. Prognostic significance of lymphocyte infiltration following preoperative chemoradiotherapy and hyperthermia for esophageal cancer. Int J Radiat Oncol Biol Phys 2001; 49: 1259–1266
   PubMed Web of Science ®Google Scholar
• Ohga T, Kimura Y, Futatsugi M, Miyazaki M, Saeki H, Nozoe T. Surgical and oncological advances in the treatment of esophageal cancer. Surgery 2002; 131: S28–S34
   Google Scholar
• Jones EL, Samulski TV, Dewhirst MW, Alvarez-Secord A, Berchuck A, Clarke-Pearson D, Havrilesky LJ, Soper J, Prosnitz LR. A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 2003; 98: 277–282
   PubMed Web of Science ®Google Scholar
• Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van der, Velden J, Burger C, et al. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer 2005; 104: 763–770
   PubMed Web of Science ®Google Scholar
• Sreenivasa G, Hildebrandt B, Kummel S, Jungnickel K, Cho CH, Tilly W, Bohmer D, Budach V, Felix R, Wust P. Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer >/=FIGO IIB ‘bulky’. Int J Radiat Oncol Biol Phys 2006; 66: 1159–1167
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gonzalez GD. The Dutch Deep Hyperthermia Trial: Results in cervical cancer. Int J Hyperthermia 2002; 18: 1–12
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Drager J, Ludemann L, Sreenivasa G, Tullius SG, Amthauer H, Neuhaus P, Felix R, Riess H. Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: A pilot study. Int J Hyperthermia 2004; 20: 359–369
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA. Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma. Cancer Res 1988; 48: 2693–2697
   PubMed Web of Science ®Google Scholar
• Pfeffer MR, Teicher BA, Holden SA, al Achi A, Herman TS. The interaction of cisplatin plus etoposide with radiation +/− hyperthermia. Int J Radiat Oncol Biol Phys 1990; 19: 1439–1447
   PubMed Web of Science ®Google Scholar
• Overgaard J, Radacic MM, Grau C. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo. Cancer Res 1991; 51: 707–711
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA, Holden SA, Pfeffer MR, Jones SM. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma. Cancer Res 1990; 50: 2734–2740
   PubMed Web of Science ®Google Scholar
• Rao BS, Devi PU. Response of mouse sarcoma-180 to cis-platin in combination with radiation & hyperthermia. Indian J Med Res 1996; 103: 315–322
   PubMedGoogle Scholar
• Ressel A, Schmitt O, Weiss C, Feyerabend T. Therapeutic outcome and side-effects after radiotherapy, chemotherapy and/or hyperthermia treatment of head and neck tumour xenografts. Eur J Cancer 2002; 38: 594–601
   PubMedGoogle Scholar
• Seegenschmiedt MH, Sauer R, Miyamoto C, Chalal JA, Brady LW. Clinical experience with interstitial thermoradiotherapy for localized implantable pelvic tumors. Am J Clin Oncol 1993; 16: 210–222
   PubMedGoogle Scholar
• Gonzalez GD, van Dijk JD, Blank LE. Radiotherapy and hyperthermia. Eur J Cancer 1995; 31A: 1351–1355
   PubMedGoogle Scholar
• Prionas SD, Kapp DS, Goffinet DR, Ben Yosef R, Fessenden P, Bagshaw MA. Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994; 28: 151–162
   PubMed Web of Science ®Google Scholar
• Fatehi D, van der ZJ, Wielheesen DH, Van Wieringen WN, van Rhoon GC. Intra-luminal thermometry: Is tissue type assignment a necessity for thermal analysis?. Int J Hyperthermia 2006; 22: 463–473
   PubMed Web of Science ®Google Scholar
• Richel O, Zum Vorde Sive Vording PJ, Rietbroek R, van der Velden J, van Dijk JD, Schilthuis MS, Westermann AM. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. Gynecol Oncol 2004; 95: 680–685
   PubMed Web of Science ®Google Scholar
• Westermann AM, Grosen EA, Katschinski DM, Jager D, Rietbroek R, Schink JC, Tiggelaar CL, Jager E, Zum Vorde Sive Vording PZ, Neuman A, et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer 2001; 37: 1111–1117
   PubMed Web of Science ®Google Scholar
• Westermann AM, Wiedemann GJ, Jager E, Jager D, Katschinski DM, Knuth A, Sum Vorde Sive Vording PZ, van Dijk JD, Finet J, Neumann A, et al. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8°C whole-body hyperthermia for metastatic soft tissue sarcoma. Oncology 2003; 64: 312–321
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Drager J, Kerner T, Deja M, Loffel J, Stroszczynski C, Ahlers O, Felix R, Riess H, Wust P. Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: A phase I/II study. Int J Hyperthermia 2004; 20: 317–333
   PubMed Web of Science ®Google Scholar
• Bakhshandeh A, Bruns I, Traynor A, Robins HI, Eberhardt K, Demedts A, Kaukel E, Koschel G, Gatzemeier U, Kohlmann T, et al. Ifosfamide, carboplatin and etoposide combined with 41.8°C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer 2003; 39: 339–345
   PubMedGoogle Scholar
• Kerner T, Hildebrandt B, Ahlers O, Deja M, Riess H, Draeger J, Wust P, Gerlach H. Anaesthesiological experiences with whole body hyperthermia. Int J Hyperthermia 2003; 19: 1–12
   PubMed Web of Science ®Google Scholar
• Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, Nierhaus A, Hossfeld DK. Whole-body hyperthermia (41.8°C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: A phase II study. Ann Oncol 2002; 13: 1197–1204
   PubMed Web of Science ®Google Scholar
• Wust P, Riess H, Hildebrandt B, Loffel J, Deja M, Ahlers O, Kerner T, von Ardenne A, Felix R. Feasibility and analysis of thermal parameters for the whole-body-hyperthermia system IRATHERM-2000. Int J Hyperthermia 2000; 16: 325–339
   PubMed Web of Science ®Google Scholar
• Katschinski DM, Wiedemann GJ, Mentzel M, Mulkerin DL, Touhidi R, Robins HI. Optimization of chemotherapy administration for clinical 41.8°C whole body hyperthermia. Cancer Lett 1997; 115: 195–199
   PubMed Web of Science ®Google Scholar
• Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, et al. Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1997; 15: 158–164
   PubMed Web of Science ®Google Scholar
• Wiedemann GJ, Robins HI, Gutsche S, Mentzel M, Deeken M, Katschinski DM, Eleftheriadis S, Crahe R, Weiss C, Storer B, et al. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma. Eur J Cancer 1996; 32A: 888–892
   PubMedGoogle Scholar
• Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d’Oleire F, Longo W, Heiss C. Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1993; 11: 1787–1794
   PubMed Web of Science ®Google Scholar
• van der Zee J, van Rhoon GC, Wike-Hooley JL, Faithfull NS, Reinhold HS. Whole-body hyperthermia in cancer therapy: A report of a phase I–II study. Eur J Cancer Clin Oncol 1983; 19: 1189–1200
   PubMedGoogle Scholar
• Ohtsubo T, Saito H, Tanaka N, Tsuzuki H, Saito T, Kano E. In vitro effect of hyperthermia on chemoenhancement and uptake of cisplatin in human pharyngeal carcinoma KB cells. Chemotherapy 1997; 43: 43–50
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Maehara Y, Baba H, Takahashi I, Kusumoto H, Ohno S, Sugimachi K. Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. Br J Cancer 1993; 68: 259–263
   PubMedGoogle Scholar
• Wang X, Chow LS, Nicholls JM, Kwong DL, Sham JS, Wong YC, Tsao SW. Significance of scheduling on the cytotoxicity of radiation and cisplatin combination treatment in nasopharyngeal carcinoma cells. Anticancer Drugs 2002; 13: 957–964
   PubMedGoogle Scholar
• Raaphorst GP, Cybulski SE, Sobol R, Ng CE. The response of human breast tumour cell lines with altered polymerase beta levels to cisplatin and radiation. Anticancer Res 2001; 21: 2079–2083
   PubMed Web of Science ®Google Scholar
• Kyriazis AP, Kyriazis AA, Yagoda A. Time dependence of the radiation-modifying effect of cis-diamminedichloroplatinum II (cisplatin, DDP) on human urothelial cancer grown in nude mice. Cancer Invest 1986; 4: 217–222
   PubMed Web of Science ®Google Scholar
• Wilkins DE, Heller DP, Raaphorst GP. Inhibition of potentially lethal damage recovery by cisplatin in a brain tumor cell line. Anticancer Res 1993; 13: 2137–2142
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Miao J, Ng CE. Cisplatin and mild hyperthermia in radiosensitization to low dose rate irradiation in human ovarian carcinoma cells. Anticancer Res 1997; 17: 3469–3472
   PubMedGoogle Scholar
• Raaphorst GP, Miao J, Stewart D, Ng CE. Interactions of mild hyperthermia, cisplatin and split dose irradiation in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1998; 41: 491–496
   PubMed Web of Science ®Google Scholar
• Bergs JWJ, Haveman J, ten Cate R, Medema JP, Franken NAP, van Bree C. Effect of 41°C and 43°C on cisplatin-radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin. Oncol Rep, in press
   Google Scholar
• Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–790
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Maio J, Ng CE, Stewart DJ. Concomitant treatment with mild hyperthermia, cisplatin and low dose-rate irradiation in human ovarian cancer cells sensitive and resistant to cisplatin. Oncol Rep 1998; 5: 971–977
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Yang H, Wilkins DE, Ng CE. Cisplatin, hyperthermia and radiation treatment in human cisplatin-sensitive and resistant glioma cell lines. Int J Hyperthermia 1996; 12: 801–812
   PubMed Web of Science ®Google Scholar
• Armour EP, Raaphorst GP. Long duration mild temperature hyperthermia and brachytherapy. Int J Hyperthermia 2004; 20: 175–189
   PubMed Web of Science ®Google Scholar
• Ben Hur E, Bronk BV, Elkind MM. Thermally enhanced radiosensitivity of cultured Chinese hamster cells. Nat New Biol 1972; 238: 209–11
   PubMedGoogle Scholar
• Ling CC, Robinson E. Moderate hyperthermia and low dose rate irradiation. Radiat Res 1988; 114: 379–384
   PubMed Web of Science ®Google Scholar
• Wang Z, Armour EP, Corry PM, Martinez A. Elimination of dose-rate effects by mild hyperthermia. Int J Radiat Oncol Biol Phys 1992; 24: 965–973
   PubMed Web of Science ®Google Scholar
• Spiro IJ, McPherson S, Cook JA, Ling CC, DeGraff W, Mitchell JB. Sensitization of low-dose-rate irradiation by nonlethal hyperthermia. Radiat Res 1991; 127: 111–114
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Heller DP, Bussey A, Ng CE. Thermal radiosensitization by 41°C hyperthermia during low dose-rate irradiation in human normal and tumour cell lines. Int J Hyperthermia 1994; 10: 263–270
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Bussey A, Heller DP, Ng CE. Comparison of thermoradiosensitization in two human melanoma cell lines and one fibroblast cell line by concurrent mild hyperthermia and low-dose-rate irradiation. Radiat Res 1994; 137: 338–345
   PubMed Web of Science ®Google Scholar
• Armour E, Wang ZH, Corry P, Martinez A. Equivalence of continuous and pulse simulated low dose rate irradiation in 9L gliosarcoma cells at 37 and 41 C. Int J Radiat Oncol Biol Phys 1992; 22: 109–114
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Ng CE, Shahine B. Comparison of radiosensitization by 41°C hyperthermia during low dose rate irradiation and during pulsed simulated low dose rate irradiation in human glioma cells. Int J Radiat Oncol Biol Phys 1999; 44: 185–188
   PubMedGoogle Scholar
• Mitchel RE, Chan A, Smith BP, Child SD, Paterson MC. The effects of hyperthermia and ionizing radiation in normal and ataxia telangiectasia human fibroblast lines. Radiat Res 1984; 99: 627–635
   PubMed Web of Science ®Google Scholar
• Mitchel RE, Smith BP, Wheatly N, Chan A, Child S, Paterson MC. Sensitivity of hyperthermia-treated human cells to killing by ultraviolet or gamma radiation. Radiat Res 1985; 104: 234–241
   PubMed Web of Science ®Google Scholar
• Mitchel RE, Birnboim HC. Triggering of DNA strand breaks by 45°C hyperthermia and its influence on the repair of gamma-radiation damage in human white blood cells. Cancer Res 1985; 45: 2040–2045
   PubMed Web of Science ®Google Scholar
• Dynlacht JR, Xu M, Pandita RK, Wetzel EA, Roti Roti JL. Effects of heat shock on the Mre11/Rad50/Nbs1 complex in irradiated or unirradiated cells. Int J Hyperthermia 2004; 20: 144–156
   PubMed Web of Science ®Google Scholar
• Kampinga HH, Dynlacht JR, Dikomey E. Mechanism of radiosensitization by hyperthermia (≥43°C) as derived from studies with DNA repair defective mutant cell lines. Int J Hyperthermia 2004; 20: 131–139
   PubMed Web of Science ®Google Scholar
• Seno JD, Dynlacht JR. Intracellular redistribution and modification of proteins of the Mre11/Rad50/Nbs1 DNA repair complex following irradiation and heat-shock. J Cell Physiol 2004; 199: 157–170
   PubMed Web of Science ®Google Scholar
• Larsson C, Ng CE. p21+/+ (CDKN1A+/+) and p21−/− (CDKN1A−/−) human colorectal carcinoma cells display equivalent amounts of thermal radiosensitization. Radiat Res 2003; 160: 205–209
   PubMed Web of Science ®Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization: Mode of action and clinical relevance. Int J Radiat Biol 2001; 77: 399–408
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Ng CE, Yang DP. Thermal radiosensitization and repair inhibition in human melanoma cells: A comparison of survival and DNA double strand breaks. Int J Hyperthermia 1999; 15: 17–27
   PubMed Web of Science ®Google Scholar
• Sakkers RJ, Filon AR, Brunsting JF, Kampinga HH, Konings AW, Mullenders LH. Selective inhibition of repair of active genes by hyperthermia is due to inhibition of global and transcription coupled repair pathways. Carcinogenesis 1995; 16: 743–748
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Feeley MM. Hyperthermia radiosensitization in human glioma cells comparison of recovery of polymerase activity, survival, and potentially lethal damage repair. Int J Radiat Oncol Biol Phys 1994; 29: 133–139
   PubMed Web of Science ®Google Scholar
• Deorukhakar VV, Anjaria KB, Rao BS. Modification of radiation-induced damage by hyperthermia–role of repair processes. Int J Hyperthermia 1993; 9: 803–810
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Azzam EI, Feeley M. Potentially lethal radiation damage repair and its inhibition by hyperthermia in normal hamster cells, mouse cells, and transformed mouse cells. Radiat Res 1988; 113: 171–182
   PubMed Web of Science ®Google Scholar
• Roti Roti JL. Heat-induced cell death and radiosensitization: Molecular mechanisms. Natl Cancer Inst Monogr 1982; 61: 3–10
   PubMedGoogle Scholar
• Song CW, Shakil A, Osborn JL, Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. Int J Hyperthermia 1996; 12: 367–373
   PubMed Web of Science ®Google Scholar
• Jones EL, Prosnitz LR, Dewhirst MW, Marcom PK, Hardenbergh PH, Marks LB, Brizel DM, Vujaskovic Z. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res 2004; 10: 4287–4293
   PubMed Web of Science ®Google Scholar
• Wallen CA, Colby TV, Stewart JR. Cell kill and tumor control after heat treatment with and without vascular occlusion in RIF-1 tumors. Radiat Res 1986; 106: 215–223
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Solesvik OV, Brustad T. Tumour growth delay, cell inactivation and vascular damage following hyperthermic treatment of a human melanoma xenograft. Eur J Cancer Clin Oncol 1984; 20: 1295–1305
   PubMedGoogle Scholar
• Rofstad EK, Brustad T. Primary and secondary cell death in human melanoma xenografts following hyperthermic treatment. Cancer Res 1986; 46: 355–361
   PubMed Web of Science ®Google Scholar
• Molls M. Hyperthermia—the actual role in radiation oncology and future prospects. Part I. Strahlenther Onkol 1992; 168: 183–190
   PubMedGoogle Scholar
• Armour EP, McEachern D, Wang Z, Corry PM, Martinez A. Sensitivity of human cells to mild hyperthermia. Cancer Res 1993; 53: 2740–2744
   PubMed Web of Science ®Google Scholar
• van der Zee J, van Rhoon GC. Hyperthermia is effective in improving clinical radiotherapy results. Int J Radiat Oncol Biol Phys 2006; 66: 633–634
   PubMedGoogle Scholar
• Dahl O. Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity. Hyperthermia and Oncology, M Urano, E Douple, Utrecht, VSP BV 1994; 4: 9–29
   Google Scholar
• Crul M, van Waardenburg RC, Beijnen JH, Schellens JH. DNA-based drug interactions of cisplatin. Cancer Treat Rev 2002; 28: 291–303
   PubMedGoogle Scholar
• Rybak LP, Whitworth CA. Ototoxicity: Therapeutic opportunities. Drug Discov Today 2005; 10: 1313–1321
   PubMed Web of Science ®Google Scholar
• Zhu WG, Seno JD, Beck BD, Dynlacht JR. Translocation of MRE11 from the nucleus to the cytoplasm as a mechanism of radiosensitization by heat. Radiat Res 2001; 156: 95–102
   PubMed Web of Science ®Google Scholar
• Xu M, Myerson RJ, Hunt C, Kumar S, Moros EG, Straube WL, Roti Roti JL. Transfection of human tumour cells with Mre11 siRNA and the increase in radiation sensitivity and the reduction in heat-induced radiosensitization. Int J Hyperthermia 2004; 20: 157–162
   PubMed Web of Science ®Google Scholar
• Yin HL, Suzuki Y, Matsumoto Y, Tomita M, Furusawa Y, Enomoto A, Morita A, Aoki M, Yatagai F, Suzuki T, et al. Radiosensitization by hyperthermia in the chicken B-lymphocyte cell line DT40 and its derivatives lacking nonhomologous end joining and/or homologous recombination pathways of DNA double-strand break repair. Radiat Res 2004; 162: 433–441
   PubMed Web of Science ®Google Scholar
• Bergs JW, Franken NA, ten Cate R, van Bree C, Haveman J. Effects of cisplatin and gamma-irradiation on cell survival, the induction of chromosomal aberrations and apoptosis in SW-1573 cells. Mutat Res 2006; 594: 148–154
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003; 13: 13–21
   PubMed Web of Science ®Google Scholar
• Haveman J, Castro KN, Rodermond HM, van Bree C, Franken NA, Stalpers LJ, Zdzienicka MZ, Peters GJ. Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil. Oncol Rep 2004; 12: 187–192
   PubMedGoogle Scholar
• Huang X, Okafuji M, Traganos F, Luther E, Holden E, Darzynkiewicz Z. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 2004; 58: 99–110
   PubMed Web of Science ®Google Scholar
• van Hennik MB, van der Vijgh WJ, Klein I, Elferink F, Vermorken JB, Winograd B, Pinedo HM. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 1987; 47: 6297–6301
   PubMed Web of Science ®Google Scholar
• van der Zee J, de Bruijne M, van Rhoon GC. Letter to the editor. Int J Hyperthermia 2006; 22: 433–447
   PubMedGoogle Scholar
• Dewhirst MW, Thrall D, Vujaskovic Z. In reply to van der Zee et al. Int J Hyperthermia 2006; 22: 437–444
   Google Scholar
• Raaphorst GP, Chabot P, Doja S, Wilkins D, Stewart D, Ng CE. Effect of hyperthermia on cisplatin sensitivity in human glioma and ovarian carcinoma cell lines resistant and sensitive to cisplatin treatment. Int J Hyperthermia 1996; 12: 211–222
   PubMed Web of Science ®Google Scholar
• Hettinga JV, Lemstra W, Meijer C, Dam WA, Uges DR, Konings AW, De Vries EG, Kampinga HH. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and–resistant tumour cells. Br J Cancer 1997; 75: 1735–1743
   PubMed Web of Science ®Google Scholar
• Beketic-Oreskovic L, Jaksic M, Oreskovic S, Osmak M. Hyperthermic modulation of resistance to cis-diamminedichloroplatinum (II) in human larynx carcinoma cells. Int J Hyperthermia 1997; 13: 205–214
   PubMed Web of Science ®Google Scholar
• Hettinga JV, Lemstra W, Meijer C, Mulder NH, Konings AW, De Vries EG, Kampinga HH. Hyperthermic potentiation of cisplatin toxicity in a human small cell lung carcinoma cell line and a cisplatin resistant subline. Int J Hyperthermia 1994; 10: 795–805
   PubMed Web of Science ®Google Scholar